Clinical study claims improved wrinkle reduction
Growth in the men’s grooming sector is a specific target for Sederma’s Matrixyl 3000, a matrikine combination designed to recreate conditions conducive to cell and matrix turnover, following a new clinical study comparing its effects with a placebo.
Growth in the men’s grooming sector is a specific target for Sederma’s Matrixyl 3000, a matrikine combination designed to recreate conditions conducive to cell and matrix turnover, following a new clinical study comparing its effects with a placebo.
Matrikines are small endogenous peptides derived from matrix proteolysis, which act as cell messengers capable of regulating the sequence of events required for skin repair, effectively wound healing. To a certain degree, says Sederma, wrinkles may be considered localised defects due to deficient repair related to the ageing of the cutaneous functions of tissue repair and turnover.
The in-vivo study tested Matrixyl 3000 formulated at 4% on two panels of 24 men with a mean age of 45.5+/-6 years conducting half face daily application for two months. The ingredient was found to reduce the mean depth of the main wrinkle by -10.2% and its volume by -17.1%. Measuring an additional parameter, it was also found that as the wrinkle depth decreases its spread angle increases.